Beyond Air (XAIR) has disclosed a new risk, in the Corporate Activity and Growth category.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The analyst notes that the proposed NeuroNOS Ltd. acquisition by Beyond Air remains contingent on definitive agreements, regulatory approvals, and other closing conditions that may never be satisfied. Failure to consummate the deal could lead to sunk transaction costs, distraction of management, and strategic uncertainty regarding NeuroNOS Ltd.’s future.
He further observes that, if the transaction does not proceed, Beyond Air may be forced to seek alternative strategic or financing arrangements for NeuroNOS Ltd. on potentially unfavorable terms, which could in turn materially and adversely impact Beyond Air’s business, overall financial condition, and the market price of its common stock.
Overall, Wall Street has a Moderate Buy consensus rating on XAIR stock based on 2 Buys and 1 Hold.
To learn more about Beyond Air’s risk factors, click here.